> Recent 2023–2024 chemical biology studies position DCAF11/WDR23 as an increasingly actionable CRL4 substrate receptor for targeted protein degradation, extending the E3-ligase toolbox beyond CRBN and VHL. Drug-like covalent DCAF11 ligands and DCAF11-recruiting degraders were reported to drive degradation of proteins such as BRD4 and to show antitumor activity in cells and, for some compounds, in mouse xenograft models, supporting expert views that DCAF11 is now a bona fide TPD platform rather than merely a poorly characterized adaptor. URLs: https://doi.org/10.1038/s41467-023-43657-6 ; https://doi.org/10.1371/journal.pbio.3002550 ; https://doi.org/10.1158/1535-7163.MCT-24-0219 (pqac-00000001, pqac-00000012, pqac-00000013)
>
> Mechanistically, these advances build on foundational evidence that DCAF11/WDR23 is a DDB1-CUL4-associated substrate receptor that can recognize and regulate specific targets, most notably NRF2/NFE2L2, independently of the canonical KEAP1-CUL3 pathway. This has made DCAF11 especially interesting to experts because it links degrader chemistry directly to a biologically validated stress-response node with implications for cancer resistance, redox biology, and cytoprotection. URLs: https://doi.org/10.1371/journal.pgen.1006762 ; https://doi.org/10.1038/s41598-019-50877-8 (pqac-00000004, pqac-00000006, pqac-00000009)
>
> Authoritative 2024 work further strengthens the view that WDR23 is not only relevant to degradation technology but also to physiology: loss of WDR23 increased IDE expression through NRF2-dependent transcription, reduced circulating insulin, altered insulin signaling, and was associated with altered HbA1c in a large human aging cohort, highlighting a plausible metabolic-disease connection. In parallel, 2024 nervous-system studies reinforced that WDR23-mediated NRF2 proteostasis shapes hippocampal antioxidant programs, underscoring broader tissue-specific roles in oxidative-stress adaptation. URLs: https://doi.org/10.1007/s11357-024-01196-y ; https://doi.org/10.1016/j.mad.2024.111914 (pqac-00000005, pqac-00000010)
>
> Overall, the current expert consensus from these studies is that DCAF11/WDR23 should be viewed as a multifunctional CRL4 substrate receptor at the intersection of proteostasis, oxidative-stress control, cell-state regulation, and emerging therapeutic modality design. The major open question is no longer whether DCAF11 is druggable, but how broadly and selectively its endogenous substrate-recognition biology can be harnessed across cancer, neurodegeneration, and metabolic disease contexts. (pqac-00000001, pqac-00000005, pqac-00000010, pqac-00000012, pqac-00000013)


*Blockquote: This blockquote summarizes recent expert-relevant developments on DCAF11/WDR23 across targeted protein degradation, oxidative-stress regulation, and metabolic disease links. It is useful as a concise synthesis of why DCAF11 has become a notable E3 ligase substrate receptor in current research.*